Quarterly report pursuant to Section 13 or 15(d)

License Agreements - Additional Information (Detail)

v3.3.1.900
License Agreements - Additional Information (Detail)
 6 Months Ended
Dec. 15, 2015
USD ($)
Dec. 15, 2015
GBP (£)
Dec. 14, 2015
USD ($)
Oct. 16, 2012
USD ($)
Nov. 30, 2015
USD ($)
Nov. 30, 2015
GBP (£)
Jun. 30, 2016
USD ($)
Jun. 30, 2016
GBP (£)
Jan. 08, 2016
USD ($)
Nov. 30, 2015
GBP (£)
May. 31, 2015
USD ($)
Commitments and Contingencies [Line Items]                      
Maximum contingent payment         $ 930,000         £ 600,000  
Accrued license fees         $ 1,860,000           $ 930,000
Annual license fee | £           £ 300,000          
Asset purchase, cash paid       $ 3,500,000              
Asset Purchase Agreement Aggregate Consideration Paying Period         10 years 10 years          
Accrued milestone payments         $ 2,500,000       $ 1,500,000   $ 2,500,000
Subsequent Event                      
Commitments and Contingencies [Line Items]                      
License payment $ 915,000 £ 600,000 $ 915,000                
Milestone Payments                      
Commitments and Contingencies [Line Items]                      
Royalty on every net sales         5.00%         5.00%  
Development Milestone Payments                      
Commitments and Contingencies [Line Items]                      
Asset Purchase Agreement Aggregate Consideration Paying Period         10 years 10 years          
Minimum annual license maintenance fees         $ 150,000            
First dosing in a U.S. Phase 3 trial or non-US equivalent | Milestone Payments                      
Commitments and Contingencies [Line Items]                      
Payment to acquire other assets         1,500,000            
First dosing in a U.S. Phase 3 trial or non-US equivalent | Development Milestone Payments                      
Commitments and Contingencies [Line Items]                      
Payment to acquire other assets         1,000,000            
First US new drug application approval by the FDA or other non-U.S. approval | Milestone Payments                      
Commitments and Contingencies [Line Items]                      
Payment to acquire other assets         5,000,000            
Biologic License Application with the FDA or non-U.S. equivalent regulatory body | Development Milestone Payments                      
Commitments and Contingencies [Line Items]                      
Payment to acquire other assets         $ 500,000            
FDA approval or approval by another non-U.S. equivalent regulatory body | Development Milestone Payments                      
Commitments and Contingencies [Line Items]                      
Royalty on every net sales         7.50%         7.50%  
Scenario, Forecast                      
Commitments and Contingencies [Line Items]                      
Maximum contingent payment             $ 930,000 £ 600,000